GHRH Analogue — Egrifta / TransCon hGH
A stabilised synthetic analogue of growth hormone-releasing hormone (GHRH) with FDA approval for HIV-associated lipodystrophy. Tesamorelin stimulates pulsatile GH release from the pituitary, producing significant visceral fat reduction, improved body composition, and cognitive benefits — with a more physiologically natural GH profile than exogenous GH administration.
01 — Research Summary
Tesamorelin has a robust clinical evidence base anchored by its FDA approval programme, with additional research expanding into cognitive function, non-alcoholic fatty liver disease, and general longevity applications.
18% reduction in visceral adipose tissue. The pivotal trials leading to FDA approval demonstrated tesamorelin reduced visceral fat by approximately 18% over 26 weeks in HIV-positive patients with lipodystrophy — the most significant pharmacologically-driven visceral fat reduction documented at the time.
Significant improvement in mild cognitive impairment. A randomised controlled trial in adults with mild cognitive impairment showed tesamorelin treatment over 20 weeks significantly improved executive function and verbal memory versus placebo — among the most compelling peptide-based cognitive data available.
Significant hepatic fat reduction in NAFLD. Research demonstrated tesamorelin significantly reduced liver fat in patients with non-alcoholic fatty liver disease, with histological improvement in approximately 35% of treated patients — expanding the therapeutic profile beyond lipodystrophy.
Preserved physiological GH release pattern. Unlike exogenous growth hormone injections, tesamorelin preserves pulsatile GH secretion — maintaining the natural feedback mechanisms that regulate GH activity. This is associated with better safety profile and reduced IGF-1 overstimulation risk.
02 — Mechanism of Action
Tesamorelin works upstream of growth hormone — stimulating the pituitary to release GH naturally rather than bypassing the regulatory system with exogenous GH. This distinction matters significantly for both safety and physiological outcome.
Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary gland. The trans-3-hexenoic acid modification stabilises the peptide against plasma degradation, extending its activity while maintaining authentic GHRH receptor agonism.
Unlike continuous GH infusion, tesamorelin preserves the pulsatile pattern of GH release — mimicking the natural somatotropic rhythm. Pulsatile release is physiologically significant; many of GH's effects are pattern-dependent rather than simply concentration-dependent.
GH released in response to tesamorelin travels to the liver, stimulating production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH's metabolic and anabolic effects including protein synthesis, lipolysis, and tissue maintenance.
The GH/IGF-1 axis activates lipolysis preferentially in visceral adipose tissue — the metabolically active abdominal fat associated with cardiovascular risk. This selectivity for visceral over subcutaneous fat distinguishes tesamorelin from general weight loss approaches.
Because tesamorelin acts upstream through the pituitary axis, the normal hypothalamic-pituitary feedback mechanisms remain intact. This prevents the runaway IGF-1 elevation seen with direct GH administration and maintains physiological regulation.
Tesamorelin works with your body's regulatory system rather than bypassing it. The pituitary still responds to somatostatin inhibition, the liver still modulates IGF-1 production based on nutritional status, and growth hormone receptor downregulation doesn't occur. This physiological preservation is why many longevity-focused practitioners prefer GHRH analogues over direct GH administration.
03 — Dosing Protocols
Tesamorelin has a well-established clinical dosing protocol from its FDA approval programme. Off-label longevity use typically mirrors the approved protocol.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard / approved dose | 2 mg | Once daily | Ongoing | FDA-approved protocol. Subcutaneous injection into abdomen, thighs, or buttocks. Rotate sites. |
| Longevity protocol | 1–2 mg | 5 days on / 2 off | 12–16 weeks | Community adaptation to allow pituitary rest. Some prefer cycling over continuous use. |
| Conservative start | 1 mg | Daily × 4 weeks | 4 weeks, then reassess | Lower initial dose to assess water retention and GI tolerance before escalating. |
| Combined GH protocol | 1–2 mg + Ipamorelin | Daily | 8–12 weeks | GHRH + GHRP combination for synergistic GH pulse amplification. |
Water retention and joint aches are common during the first 2–4 weeks and typically resolve. Monitor fasting glucose as GH elevation can cause transient insulin resistance. Not recommended in active malignancy. IGF-1 monitoring every 8–12 weeks is recommended in long-term use.
04 — Community Experiences
Tesamorelin has carved out a strong position in the longevity and body composition community — valued for its FDA-approved status, GHRH mechanism, and the cognitive data from the MCI trial which is frequently referenced. Discussions centre on visceral fat reduction (particularly in metabolically compromised individuals), the comparison vs. Ipamorelin/CJC-1295 stacks, and its cognitive benefits.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"DEXA showed 1.8kg visceral fat reduction over 6 months. IGF-1 went from 140 to 220. Cognitive focus is noticeably improved — I wasn't expecting that. Water retention in weeks 1-3 then completely resolved..."
"Different mechanisms, different results. Tesamorelin specifically targets visceral fat. Ipamorelin/CJC gives more GH pulse amplitude. I ran both and found tesamorelin more targeted for metabolic fat, CJC stack better for overall body comp and sleep..."
"The RCT data on executive function and verbal memory is one of the strongest peptide-based cognitive datasets I've seen. This isn't biohacker anecdote — it's a proper trial. Filing this under 'compounds I take seriously'..."
"Weeks 1-3 I had noticeable water retention and some joint ache. Both resolved completely by week 4. Would have quit if I didn't know it was temporary. Stick with it through the adaptation phase..."